USA - engelsk - NLM (National Library of Medicine)

the oozoo co. ltd - niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4) - niacinamide 0.006 g in 0.3 ml

USA - engelsk - NLM (National Library of Medicine)

top care (topco associates llc) - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), chlorpheniramine maleate (unii: v1q0o9oj9z) (chlorpheniramine - unii:3u6io1965u), dextromethorphan hydrobromide (unii: 9d2rti9kyh) (dextromethorphan - unii:7355x3rots), phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - pain reliever/fever reducer antihistamine cough suppressant nasal decongestant - temporarily relieves the following cold/flu symptoms: minor aches and pains sore throat cough sneezing and runny nose headache stuffy nose  - minor aches and pains - sore throat - cough - sneezing and runny nose - headache - stuffy nose  - temporarily reduces fever

USA - engelsk - NLM (National Library of Medicine)

stason pharmaceuticals, inc. - mercaptopurine (unii: e7wed276i5) (mercaptopurine anhydrous - unii:pkk6muz20g) - purinethol is indicated for treatment of adult and pediatric patients with acute lymphoblastic leukemia (all) as part of a combination chemotherapy maintenance regimen. none. purinethol can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . pregnant women who receive mercaptopurine have an increased incidence of miscarriage and stillbirth (see data) . advise pregnant women of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. women receiving mercaptopurine in the first trimester of pregnancy have an increased incidence of miscarriage; the risk of malformation in offspring surviving first trimester exposure is not known. in a series of 28 women receiving mercaptopurine after the first trimester of pregnancy, 3 mothers died prior to delivery, 1 delivered a stillborn child, and 1 aborted; there were no cases of macroscopically abnormal fetuses. mercaptopurine was embryo-lethal and teratogenic in several animal species (rat, mouse, rabbit, and hamster) at doses less than the recommended human dose. there are no data on the presence of mercaptopurine or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with purinethol and for 1 week after the last dose. purinethol can cause fetal harm when administered to pregnant women [see use in specific populations (8.1)] . verify the pregnancy status in females of reproductive potential prior to initiating purinethol  [see use in specific populations (8.1)] . advise females of reproductive potential to use effective contraception during treatment with purinethol and for 6 months after the last dose. based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with purinethol and for 3 months after the last dose [see nonclinical toxicology (13.1)] . based on findings from animal studies, purinethol can impair female and male fertility [see nonclinical toxicology (13.1)] . the long-term effects of mercaptopurine on female and male fertility, including the reversibility have not been studied. safety and effectiveness of purinethol has been established in pediatric patients. use of purinethol in pediatrics is supported by evidence from the published literature and clinical experience. symptomatic hypoglycemia has been reported in pediatric patients with all receiving mercaptopurine. reported cases were in pediatrics less than 6 years of age or with a low body mass index. clinical studies of mercaptopurine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or another drug therapy. use the lowest recommended starting dosage for purinethol or increase the dosing interval to every 36-48 hours in patients with renal impairment (clcr less than 50 ml/min). adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] . use the lowest recommended starting dosage for purinethol in patients with hepatic impairment. adjust the dose to maintain absolute neutrophil count (anc) at a desirable level and for adverse reactions [see dosage and administration (2.3)] .

USA - engelsk - NLM (National Library of Medicine)

remedyrepack inc. - furosemide (unii: 7lxu5n7zo5) (furosemide - unii:7lxu5n7zo5) - edema furosemide tablets are indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. furosemide tablets are particularly useful when an agent with greater diuretic potential is desired. hypertension oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide.

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

csp "ucf borsceagov" sap - comprimate - 10 mg + 300 mg

Latvia - latvisk - Zāļu valsts aģentūra

uab valentis, lithuania - valerianae krāsošanas, absinthii krāsošanas, menthae piperitae krāsas, krāsošanas belladonnae - pilieni iekšķīgai lietošanai, šķīdums

Latvia - latvisk - Zāļu valsts aģentūra

rīgas farmaceitiskā fabrika, a/s, latvia - belladonnae krāsošanas, menthae piperitae krāsošanas, absinthii krāsas, krāsošanas valerianae - pilieni iekšķīgai lietošanai, šķīdums

Østerrike - tysk - AGES (Agentur für Gesundheit und Ernährungssicherheit)

abs-otc-vertrieb rmt gmbh - radix valerianae (auszug),folium melissae (auszug),fructus carvi (auszug) - antispasmodics in combina

Italia - italiensk - AIFA (Agenzia Italiana del Farmaco)

acarpia farmaceutici s.r.l. - antispastici in associazione con altri farmaci - antispastici in associazione con altri farmaci

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

centrul Ştiinţific de producere "uzina chimico-farmaceutică borsceagov" sap - extras belladonnae uscat + natrii hydrocarbonas - comprimate - 10 mg/300 mg